Enterprise League logo
Rafael Holdings, Inc. Logo

Rafael Holdings, Inc.

Newark, United States (US) · Health and Medical

Do you work at Rafael Holdings, Inc.?

Claim this profile to manage your company.

Verified by Enterprise League

Data quality

Complete · Accuracy

Rafael Holdings is a New Jersey-based biotechnology company focused on developing novel cancer therapies and investing in innovative oncology companies.We are dedicated to improving and extending the lives of patients through a pipeline of clinical stage compounds, including a recent merger with Cyclo Therapeutics to address Niemann Pick Type C1.Rafael Holdings distinguishes itself through its commitment to advancing multiple clinical programs, including two Phase 3 trials, and its strategic approach to transitioning towards a commercial enterprise.

Overview

Rafael Holdings is a New Jersey-based biotechnology company focused on developing novel cancer therapies and investing in innovative oncology companies.

We are dedicated to improving and extending the lives of patients through a pipeline of clinical stage compounds, including a recent merger with Cyclo Therapeutics to address Niemann Pick Type C1.

Rafael Holdings distinguishes itself through its commitment to advancing multiple clinical programs, including two Phase 3 trials, and its strategic approach to transitioning towards a commercial enterprise. We prioritize a culture of compliance and ethics, ensuring adherence to all applicable regulations and industry standards.

As a rapidly growing company, Rafael Holdings seeks a skilled Chief Compliance and Ethics Officer to lead the transformation of our compliance function.
Visit Official Website

Most teams do this before shortlisting


Contact Details

info@rafaelholdings.com

Newark, United States (US), 520 BROAD ST

Company Type

Public Limited Company

Employees

10-20

Categories

Biopharma
Life Science
Biotechnology

Awards

• 2026 OpenSee all

Products

Default Product Image
Oncological Therapeutics
Biotechnology

Rafael Holdings is dedicated to the discovery and development of novel oncological therapeutics to improve and extend the lives of patients.

N/A


Services

Default Product Image
Cyclo Therapeutics Pipeline
Biotechnology

Rafael Holdings’ investment in Cyclo Therapeutics provides access to a pipeline of novel cancer therapies, specifically focused on Niemann Pick Type C1. This represents a significant opportunity to deliver a breakthrough treatment option for patients with this challenging disease.

N/A

Companies teams usually look at after Rafael Holdings, Inc.

Comparing a few options usually leads to better decisions






  • Save companies to compare later. Useful when sharing options with your team

This is how your company profile looks to others.